Treatment News : U.S. Government Updates HIV Treatment Guidelines

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 12, 2011

U.S. Government Updates HIV Treatment Guidelines

The U.S. Department of Health and Human Services  (DHHS) issued an update to federal HIV treatment guidelines January 10, offering clarification or changes to recommendations about three antiretroviral (ARV) therapies, monitoring CD4 cells and managing ARV treatment in people with tuberculosis.

The DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents makes recommendations about the best time to start or switch therapy, the best treatments to use in various situations, ways to monitory treatment and deal with side effects and certain opportunistic infections (OIs), and a host of other issues related to ARV treatment.

In the January 10 update, the DHHS upgraded the combination of Selzentry (maraviroc) and Combivir (zidovudine plus lamivudine) from “may be acceptable, but more data needed” to “acceptable.” The guidelines panel also added recommendations for Selzentry combined with either Truvada (tenofovir plus emtricitabine) or Epzicom (abacavir plus lamivudine), placing these combinations in the category of “may be acceptable, but more data needed.”

As a result of new data about an increased risk for heart rhythm disturbances when the protease inhibitor Invirase (saquinavir) is teamed with low-dose Norvir (ritonavir), the guidelines committee downgraded this ARV combination from “alternative” to “acceptable, but use with caution.”

Other changes included new recommendations for managing ARVs in people with tuberculosis and for monitoring resistance with the integrase inhibitor Isentress (raltegravir). And some recommendations state that CD4 counts do not need to be monitored as often in some people taking ARVs, provided that their viral loads are checked every three months and that their HIV remains undetectable.

Search: DHHS guidelines, antiretroviral, adults, Selzentry, maraviroc, Invirase, saquinavir, Norvir, ritonavir, tuberculosis, CD4

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (3 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.